GKOSNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31

GLAUKOS Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026

$166.96+2.12 (+1.29%)

Close on Oct 19, 2026

Market cap: $9.82B
P/E (TTM): –
Dividend yield: –

Dividends

Glaukos has not reported a dividend

No dividend per share appears in Glaukos's annual filings since fiscal 2012.

Where these numbers come from

Parsed from the XBRL in Glaukos's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is GKOS.

Revenue growth41.5% · median 6.2%

Gross margin60.7% · median 73.7%

Operating margin-31.6% · median -13.4%

Net margin-30.7% · median -14.3%

Company	Revenue	Growth
OFIX	$833.19M	+3.0%
NVCR	$699.19M	+11.0%
GKOS	$612.84M	+41.5%
BVS	$581.85M	+3.1%
SGHT	$83.38M	+9.3%
SGP	–	–

Company

Next earnings (est.): Oct 28, 2026, after close
Exchange: NYSE
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: December 31
Employees: 1,094
Held by institutions: 100.0%
Auditor: Ernst & Young LLP
SEC CIK: 1192448

Advertisement
300 × 250